soria
@jsoriamd
SVP Oncology Global Development @Amgen, Physician-Scientist, Medical Oncologist, immune and molecular target-believer, Tweets my own
Great graphics and global overview on cancer prevalence and therapeutic improvements in this article. Overall cancer survival rates have moved from 50% end of the 70s to 67% in 2013. ourworldindata.org/cancer
Humoral Immunity in CheckPoint Inhibitors Response CPI response isn't just T cell-driven. In a 374-patient CPI cohort, @Nature study shows: ✅ Broad, stable anti-exoproteome autoantibody signatures ✅Some AAbs enhance CPI efficacy (e.g., by blocking IL-6, IFN-I, TL1A) ✅Others…
Esteban Cvitkovic (“Steve”, “El Gordo”) died on June 20, 2025. Inventor of hyperhydrated cisplatin, developer of oxaliplatin, pioneer in head and neck cancers.He had the rare gift of seeing the truth behind appearances and asking: “Is this practice truly useful to the patient?”
ctDNA/CTC-based liquid biopsies are redefining clinical oncology: enabling population screening, early relapse flagging, pharmacodynamic monitoring, and molecular profiling of resistance—all from peripheral blood. #Liquidbiopsies cell.com/cancer-cell/fu…
As of Jan 1, 2025, 18.6 million people in the U.S. are living with a history of cancer. By 2035, this is projected to exceed 22 million. Prostate, breast, & colorectal cancers lead prevalence. #Oncology #CancerSurvivorship acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…
#ASCO25 Development of acquired therapeutic resistance limits the efficacy of cancer treatments. How resistance arises, varies across cancer types & differs depending on therapeutic modalities. nature.com/articles/s4156…
Radioligand therapies harness the cytotoxic force of radiotherapy with molecular precision—emerging as a new strategy for cancers. Clinical-stage radioligand therapies landscape overview #ASCO25 nature.com/articles/d4157…
🔍 Unmet Need in Localized Prostate Cancer 🌍 1.4M new global cases (2020) 🇺🇸 In the US: •65K Low Risk •108K Intermediate Risk •43K High Risk 🎯 Goal: therapies that prevent recurrence while preserving quality of life. 📉 Only ~43% receive radiotherapy #ASCO25
#ASCO25: We will present Phase Ill data, also published in @NEJM, for metastatic SCLC, offering a new option for this aggressive cancer, leveraging the use of T-cell engagers. nejm.org/doi/full/10.10…
Presented at #ASCO25: Among patients with relapsed small-cell lung cancer after the failure of platinum-based chemotherapy, tarlatamab therapy led to a greater overall and progression-free survival benefit over chemotherapy, with fewer severe adverse events. Full DeLLphi-304…
Why add systemic therapy to radical surgery in NSCLC? 🧵 • Aim 1: ↑ cure by eradicating micrometastases (adj/neoadj) • Aim 2: Downstage tumor to enable resection • pCR ≈ surrogate for OS in chemo • TOX risk: 15–20% may not reach surgery ⚠️ CT ≠ ICB ≠ TKI #ASCO25
🚀#DLL3 innovation brought us to new frontiers in small cell lung cancer care. @Amgen’s T-cell engager technology is designed to activate the immune system to find & attack cancer cells that express DLL3. Discover how ⬇️ #ASCO25
mRNA pre-drugs: a new path in oncology drug design, with clear trade-offs. ✅ Lower production costs ✅ Extended antibody half-life ⚠️ New toxicities ⚠️ Reduced control over pharmacokinetics #ASCO25 #Oncology #DrugDevelopment #mRNAtherapeutics
Bi-specifics: not all created equal. 🧬 Tumor-targeted 🛡️ Immune-redirecting 🔥 Immune-enhancing Solid visual from #ASCO25 #TCE #CancerTreatment
Algorithmic approach to TOP1i ADCs maps tumor types & cross-resistance to optimize payload decisions. Unique opportunities in hard-to-treat cancers like GBM, HNSCC, PDAC? . #ADC #PrecisionOncology #ASCO25
Carcinoma of Unknown Primary: Cancer without a past 🧬 Early dissemination 🛡️Immune editing of the primary 🧪CK20+, CDX2+, SATB2+ → treat colon-like 🧭Let biology, not anatomy, guide therapy Not a diagnostic failure — a metastatic strategy. nejm.org/doi/full/10.10… #ASCO25…
🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency. 🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric. But not all MSI-H/dMMR tumors are alike: 1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response 2️⃣ PTEN/AKT1 mutations → ICI resistance Checkpoint blockade is now 1L in CRC…
Cancer-associated Cachexia is a lethal metabolic syndrome marked by systemic inflammation, CNS appetite dysregulation, & muscle/fat loss—better characterized with imaging. Prevalent in cancers like pancreatic/lung, it's linked to IL-6, GDF-15, & tumor-driven energy drain. Trials…
CHIP is a common, age-related condition where mutated blood stem cells expand without causing blood disorders. CHIP raises the risk of hematological malignancies, chronic inflammatory diseases (like heart & lung disease), & lung cancer. This manuscript shows that CHIP somatic…
ADC’s Bystander Effect may be crucial for efficacy! In a provocative recent paper, HER2 ADC’s payload may not need ADC internalization for efficacy ! Activity may rely on extracellular proteases, such as cathepsin L (CTSL). This extracellular release in the TME appears to kill…
The 2025 Annual Report on the Status of Cancer confirms a continued decline in overall cancer mortality (Cancer death rates decreased by 1.7%/ year for men & 1.3%/ year for women from 2018 to 2022) yet the pace of improvement has slowed during the COVID-19 pandemic. Lung cancer…
